We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00209456
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : May 16, 2007
Information provided by:
GE Healthcare

Brief Summary:
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical diagnosis of an independent expert consensus panel used as the standard of truth.

Condition or disease Intervention/treatment Phase
Lewy Body Dementia Non-DLB Dementia Alzheimer's Vascular Dementia Drug: DatSCAN Phase 3

Detailed Description:
GEHC had decided notto provide this detail

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 326 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title
Study Start Date : November 2003

Primary Outcome Measures :
  1. Sensitivity and specificity of DaTSCAN SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects.

Secondary Outcome Measures :
  1. Accuracy, positive predictive value and negative predictive value of DaTSCAN SPECT
  2. Semi-quantitative analysis of the striatal uptake ratios of DaTSCAN SPECT images.
  3. Impact of DaTSCAN SPECT analysis on the confidence of diagnosis.
  4. Findings in relation to probable, possible and no-DLB.
  5. Efficacy analysis at 12-month follow-up period.
  6. Safety profile

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be adults between 55 to 90 years of age with an established diagnosis for dementia in accordance with DSM-IV criteria and have to fulfil at least one of the following: The ICC criteria for probable and possible DLB, the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) for Alzheimer's Disease (AD), or the National Institute of Neurological and Communicative Disorders and Association Internationale Pour la Recherche et l'Enseignement en Neurosciences (NINCS-AIREN) for Vascular Dementia (VaD).

Exclusion Criteria:

  • Subjects are not eligible if they have a Mini Mental State Examination (MMSE) score of <10 and use medication known or suspected to interact with the striatal uptake DaTSCAN to the dopamine transporter.
  • Furthermore subjects are not eligible if they were diagnosed with idiopathic Parkinson's Disease (PD), with persistent severe depression, normal pressure hydrocephalus, multiple system atrophy, cortico-basal degeneration or Huntington's Chorea Disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00209456

Layout table for location information
Amersham Buchler GmbH Co. KG
Ismaning, Germany
Sponsors and Collaborators
GE Healthcare
Layout table for investigator information
Study Director: Marc Pignot, PhD GE Healthcare
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00209456    
Other Study ID Numbers: PDT301
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: May 16, 2007
Last Verified: May 2007
Keywords provided by GE Healthcare:
Lewy Body Dementia
non-DLB dementia
Dopamine Transporter
Striatal Uptake
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia, Vascular
Lewy Body Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Neurodegenerative Diseases
Cerebrovascular Disorders
Intracranial Arteriosclerosis
Intracranial Arterial Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders